QLTI-02. ADVERSE EVENTS IN GLIOMA SURGERY: RESULTS OF A PROSPECTIVELY COMPILED DATABASE OF A SINGLE-CENTER TERTIARY CARE HOSPITAL

Abstract

Abstract BACKGROUND Adverse events in glioma surgery can cause severe problems for patients and can be a significant burden to healthcare systems. Therefore, understanding and avoiding adverse events should be essential in centers performing glioma surgery. Nevertheless, it is still uncommon to assess adverse events in a prospective, standardized manner. In this study we want to share the findings of our prospectively compiled database for adverse events in glioma surgery. METHODS Every patient treated at our institution received a peer-reviewed, standardized discharge form focused on adverse events. Any event, that led to readmission, worsening of clinical outcome, new neurological deficits, revision surgery, contributed to death or prolonged hospital stay within 30 days of discharge was recorded and classified according to the treatment-related classification system of Clavien-Dindo (Grade 1 requiring to treatment to Grade 5 resulting in death). RESULTS In 2022 a total of n = 194 patients received glioma surgery at our institution. Surgery was performed using a common craniotomy in 145 cases (74.7%), an awake craniotomy in 16 cases (8.2%) and in 33 cases (17.0 %) a stereotactic approach for biopsy was chosen. A total of n = 44 (22.7%) adverse events were recorded among these cases. The most common adverse event was a new neurological deficit after surgery in 20 cases (10.3%) followed by non-surgery related adverse events in 10 cases (5.2%). Wound healing disorders and CSF-leaks were recorded in 8 cases (4.1%) and in 6 cases (3.1%), respectively. Clavien Dindo classification showed low-grade complications (grade 1,2) in 15.9% and high-grade complications (grade 3,4,5) in 6.6%. Revision surgery was necessary in 9 cases (4.6%). CONCLUSION Adverse events in glioma surgery are not uncommon. Understanding and classifying these events in a prospective, standardized manner may help to reduce the risk of adverse events in glioma surgery in the future.